Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 44

Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Pipeline Review, H2 2018

Summary

Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Mitogen-activated protein kinase 8 is an enzyme encoded by the MAPK8 gene. It is involved in various processes such as cell proliferation, differentiation, migration, transformation and programmed cell death. It phosphorylates the replication licensing factor CDT1, inhibiting the interaction between CDT1 and the histone H4 acetylase HBO1 to replication origins. Loss of this interaction abrogates the acetylation required for replication initiation. It promotes stressed cell apoptosis by phosphorylating key regulatory factors including p53/TP53 and Yes-associates protein YAP1. It mediates starvation-induced BCL2 phosphorylation, BCL2 dissociation from BECN1, and thus activation of autophagy.

Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 1 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Ear Nose Throat Disorders, Genito Urinary System And Sex Hormones, Oncology, Ophthalmology and Respiratory which include indications Parkinson's Disease, Acute Renal Failure (ARF) (Acute Kidney Injury), Acute Sensorineural Hearing Loss, Alzheimer's Disease, Breast Cancer, Idiopathic Pulmonary Fibrosis, Interstitial Cystitis (Painful Bladder Syndrome), Ocular Inflammation, Ocular Pain and Post-Operative Pain.

The latest report Mitogen Activated Protein Kinase 8 - Pipeline Review,, outlays comprehensive information on the Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24)

- The report reviews Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) targeted therapeutics and enlists all their major and minor projects

- The report assesses Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Overview
Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Companies Involved in Therapeutics Development
Celgene Corp
OPKO Health Inc
Xigen SA
Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Drug Profiles
brimapitide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-90001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate JNK-1, JNK-2 and p38 MAP Kinase for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JNK1, JNK2 and JNK3 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SR-3306 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Dormant Products
Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Product Development Milestones
Featured News & Press Releases
May 07, 2018: Auris Medical Receives Positive Scientific Advice from EMA on Development Plan and Regulatory Pathway for AM-111
May 04, 2018: Auris Medical Announces Publication Related to AM-111 in Peer-Reviewed Scientific Journal
Jan 04, 2018: Auris Medical Provides Update on AM-111 Development Program
Dec 28, 2017: Auris Medical to Provide Update on Its AM-111 Hearing Loss Program
Nov 28, 2017: Auris Medical Reports Top-Line Results from Phase 3 Trial of AM-111 in Sudden Deafness
Jul 05, 2017: Auris Medical Completes Enrollment of Phase 3 HEALOS Trial of AM-111 for the Treatment of Sudden Deafness
Feb 24, 2017: Auris Medical Receives FDA Fast Track Designation for AM-111 in Acute Sensorineural Hearing Loss
Jan 05, 2017: Xigens Brimapitide, an Innovative JNK Inhibitor, Delivers Positive Phase II Results in Inflammatory Eye Disease
Sep 09, 2016: Auris Medical Achieves Midpoint for Enrollment in Phase 3 Trial of AM-111 in Sudden Deafness
Jun 17, 2016: Auris Medical Initiates ASSENT Phase 3 Trial of AM-111 for Treatment of Sudden Deafness
Nov 13, 2015: Auris Medical Announces Enrollment of First Patient in HEALOS Study of AM-111 in Treatment of Idiopathic Sudden Sensorineural Hearing Loss
Jun 25, 2015: Auris Medical and Cochlear to Collaborate on Clinical Trial with AM-111 for Otoprotection during Cochlear Implant Surgery
May 04, 2015: Auris Medical Holding Provides Update on Clinical Development Plan for AM-111
May 04, 2015: Auris Medical Provides Update on Clinical Development Plan for AM-111
Nov 13, 2012: Auris Medical Announces Positive Results From Phase IIb Trial With AM-111 For Treatment Of Acute Sensorineural Hearing Loss
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Celgene Corp, H2 2018
Pipeline by OPKO Health Inc, H2 2018
Pipeline by Xigen SA, H2 2018
Dormant Projects, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Top 10 Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global Pandemic Influenza Vaccine Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Sep-2018        Price: US 3480 Onwards        Pages: 122
    Influenza vaccines treat influenza by developing antibodies in the body within two weeks after vaccination. These antibodies protect against infections with the help of the attenuated viruses in the vaccine. These vaccines contain killed or inactivated strains of the influenza virus. Scope of the Report: This report focuses on the Pandemic Influenza Vaccine in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa.......
  • Global Patent Medicine Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Sep-2018        Price: US 3480 Onwards        Pages: 120
    Today many drug companies which have produced drugs with which the public is very familiar, like Plavix®, Lipitor® and Abilify® Scope of the Report: This report focuses on the Patent Medicine in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. The worldwide market for Patent Medicine is expected to grow ......
  • Global Personal Care Products for Maternity Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Sep-2018        Price: US 3480 Onwards        Pages: 120
    Personal care products for the maternity market are a sub-segment of the overall personal care market based on product use by a specific target audience. Scope of the Report: This report focuses on the Personal Care Products for Maternity in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. The increasing ......
  • Global Vitamin Ingredients Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Sep-2018        Price: US 3480 Onwards        Pages: 139
    Vitamins are of two sorts — water soluble (A, D, E, and K) and fat soluble (vitamin B and vitamin C). Vitamin B can be of the following types B1 (thiamine), B2(riboflavin), B3 (niacin), B5 (pantothenic), B6, B12, B9, and B7. The chemical ingredients that constitute vitamins are called vitamers. Vitamins can contain multiple vitamers. For example, Vitamin A contains six vitamers — retinal, retinol, and four types of carotenoids. Human body does not produce vitamin by itself, so human beings depen......
  • 2018-2023 Global Herbal Medicine Consumption Market Report
    Published: 20-Sep-2018        Price: US 4660 Onwards        Pages: 177
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Herbal Medicine market for 2018-2023. Herbal medicine--also called botanical medicine or phytomedicine refers to using a plant's seeds, berries, roots, leaves, bark, or flowers for medicinal purposes. Herbalism has a long tradition of use outside of conventional medicine. It is becoming more mainstream as improvements in analysis and quality control along w......
  • Global Physiotherapy Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Sep-2018        Price: US 3480 Onwards        Pages: 120
    Physiotherapy is a nonsurgical treatment method, where the treatment for impairments such as injury, deformity. Scope of the Report: This report focuses on the Physiotherapy in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. The increasing use of portable physiotherapy equipment in sports will drive the ......
  • Global Wound Cleaning Market Insights, Forecast to 2025
    Published: 20-Sep-2018        Price: US 3900 Onwards        Pages: 96
    This report studies the global market size of Wound Cleaning in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Wound Cleaning in these regions. This research report categorizes the global Wound Cleaning market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities a......
  • Global Gastrointestinal Therapeutics and Diagnostics Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Sep-2018        Price: US 3480 Onwards        Pages: 117
    Gastrointestinal disorders are related to digestive system and generally affect the colon, small & large intestine and rectum. The disorders include constipation, peptic ulcer diseases and irritable bowel syndrome. The major reason and cause of GI disorders are stress, intake of medicines such as iron pills and anti-depressants and unhealthy eating habits. Symptoms of the gastrointestinal infections include pain, bloating, diarrhea, nausea and vomiting. The major drugs that dominate the gastroin......
  • Global Purified Human Proteins Market Insights, Forecast to 2025
    Published: 20-Sep-2018        Price: US 3900 Onwards        Pages: 110
    This report studies the global market size of Purified Human Proteins in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Purified Human Proteins in these regions. This research report categorizes the global Purified Human Proteins market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, mark......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs